ArticleJapanese journal of ophthalmology2026
Incidence and risk factors related to ocular adverse effects caused by S-1 chemotherapy.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify the incidence and risk factors of corneal disorders (CDs) and lacrimal passage obstruction (LPO) caused by S-1 chemotherapy. STUDY
designMulticenter prospective cohort study.
methodsThis study included patients who were administered S-1 for the first time and underwent ophthalmic evaluations for 1 year during the treatment. CD was defined as an increase of >2 points in the National Eye Institute classification. LPO was defined as an abnormality in lacrimal irrigation. Risk factors were identified via univariate and multivariate analyses.
resultsThis study enrolled 126 men and 49 women with a mean age of 68.1 (30-87) years. Over a mean follow-up of 169.6 ± 127.3 days, the incidence rates of CD and LPO were 24.6% and 14.0%, with 1-year cumulative incidence rates of 37.0% and 25.9%, respectively. The risk factors for CD were no previous use of eye drops (hazard ratio [HR] 3.45, p = 0.0955) and tear breakup time over 5 s prior to S-1 chemotherapy (HR 1.86, p = 0.0535). The risk factors for LPO were male sex (HR 5.00, p = 0.0311), primary tumor other than gastric cancer (HR 2.27, p = 0.0666), previous use of eye drops for dry eye (HR 21.16, p = 0.0035), and previous visual disturbance (HR 2.89, p = 0.0303).
conclusionThe high incidence of CD and LPO among patients undergoing S-1 chemotherapy warrants close monitoring of those with identified risk factors, especially within the first six months of chemotherapy.
Indexed as
Identifiers
42032207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.